Artiva Biotherapeutics (ARTV) Common Equity (2023 - 2026)
Artiva Biotherapeutics (ARTV) posted quarterly Common Equity of $87.8 million for Q1 2026, down 47.95% year-over-year from $168.8 million in Q1 2025, and down 20.12% quarter-over-quarter from $110.0 million in Q4 2025.
Artiva Biotherapeutics (ARTV) Common Equity (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported Common Equity for 4 consecutive years, with $87.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 47.95% year-over-year to $87.8 million; the TTM figure through Mar 2026 stood at $87.8 million (down 47.95% YoY), while the FY2025 annual figure was $110.0 million, down 41.08% from the prior year.
- Common Equity eased to $87.8 million in Q1 2026 per ARTV's latest filing, from $110.0 million in the prior quarter.
- Across five years, Common Equity topped out at $201.0 million in Q3 2024 and bottomed at -$191.1 million in Q2 2024.
- Historically, Common Equity has averaged $15.8 million across 4 years, with a median of $98.9 million in 2025.
- Annual changes were most pronounced in 2024 — Common Equity jumped 232.71% — and 2026, when it slumped 47.95%.
- Artiva Biotherapeutics' Common Equity stood at -$162.0 million in 2023, then jumped by 215.2% to $186.6 million in 2024, then sank by 41.08% to $110.0 million in 2025, then slipped by 20.12% to $87.8 million in 2026.
- Business Quant data shows ARTV's Common Equity at $87.8 million in Q1 2026, $110.0 million in Q4 2025, and $129.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Artiva Biotherapeutics | 451.28 Mn | 451.28 Mn | - | 347.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 347.50 Mn |
| Mar 31, 2026 | 87.85 Mn |
| Dec 31, 2025 | 109.97 Mn |
| Sep 30, 2025 | 129.22 Mn |
| Jun 30, 2025 | 149.04 Mn |
| Mar 31, 2025 | 168.78 Mn |
| Dec 31, 2024 | 186.64 Mn |
| Sep 30, 2024 | 201.00 Mn |
| Jun 30, 2024 | -191.10 Mn |
| Mar 31, 2024 | -174.67 Mn |
| Dec 31, 2023 | -162.02 Mn |
| Sep 30, 2023 | -151.45 Mn |
| Jun 30, 2023 | -164.26 Mn |